Canada Markets open in 2 hrs 44 mins

Today's Research Reports on Acerus Pharmaceuticals, IMV, Valeant Pharmaceuticals and BELLUS Health

NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Acerus Pharmaceuticals Corporation
https://rdinvesting.com/news/?ticker=ASP.TO

IMV Inc.
https://rdinvesting.com/news/?ticker=IMV.TO

Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/news/?ticker=VRX.TO

BELLUS Health Inc.
https://rdinvesting.com/news/?ticker=BLU.TO

Acerus Pharmaceuticals' stock had no change Friday, to close the day at $0.25. The stock recorded a trading volume of 143,600 shares, which was below its three months average volume of 252,950 shares. In the last year, Acerus Pharmaceuticals' shares have traded in a range of 0.10 - 0.52. The share price has gained 150.00% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.30 is at its 200-day moving average of $0.30. Shares of Acerus Pharmaceuticals have fallen approximately 13.79 percent year-to-date.

Access RDI's Acerus Pharmaceuticals Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

On Friday, shares of IMV recorded a trading volume of 43,447 shares, which was below the three months average volume of 79,680 shares. The stock ended the day flat at 6.54. The share price has gained 96.40% from its 52 week low with a 52 week trading range of 3.33 - 9.49. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.48 is greater than its 200-day moving average of $6.81. Shares of IMV have fallen approximately 13.17 percent year-to-date.

Access RDI's IMV Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO

Valeant Pharmaceuticals International's stock edged 0.17% lower Friday, to close the day at $30.06. The stock recorded a trading volume of 568,012 shares, which was below its three months average volume of 1,150,430 shares. In the last year, Valeant Pharmaceuticals International's shares have traded in a range of 14.01 - 36.02. The share price has gained 114.56% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $31.06 is greater than its 200-day moving average of $25.43. Shares of the company are trading at a Price to Earnings ratio of 4.40. Shares of Valeant Pharmaceuticals International have gained approximately 14.73 percent year-to-date.

Access RDI's Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX.TO

On Friday, shares of BELLUS Health recorded a trading volume of 112,416 shares, which was above the three months average volume of 85,376 shares. The stock ended the day 12.73% lower at 0.48. The share price has gained 45.45% from its 52 week low with a 52 week trading range of 0.33 - 0.62. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.55 is greater than its 200-day moving average of $0.47. Shares of BELLUS Health have gained approximately 51.35 percent year-to-date.

Access RDI's BELLUS Health Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLU.TO

Our Actionable Research on Acerus Pharmaceuticals Corporation (TSX: ASP.TO) and IMV Inc. (TSX: IMV.TO) and Valeant Pharmaceuticals International, Inc. (TSX: VRX.TO) and BELLUS Health Inc. (TSX: BLU.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com